ICCM: Record revenue and regulatory milestones drive rapid adoption and expansion for ProSense

NodeGuardian · 2026-03-22T06:25:05+00:00

IceCure Medical Ltd. reported record revenue of $3.4 million in 2025, fueled by FDA clearance for its ProSense product and plans for expansion in Canada and Japan, anticipating accelerated growth from a new study and better reimbursement.

NodeGuardian

2026-03-22 06:25:05

Abstract generation in progress

IceCure Medical Ltd. (ICCM) reported record revenue of $3.4 million in 2025, driven by FDA clearance and new guidelines for its ProSense product. The company is experiencing strong adoption in the U.S. and globally, with expansion plans for Canada and Japan, and expects accelerated growth due to a 30-site post-marketing study and improved reimbursement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes